Navigation Links
Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 27th Annual J.P. Morgan Healthcare Conference. The details are as follows:

    Date:  Monday, January 12, 2009
    Time:  8:00 a.m. - 8:30 a.m. Pacific
    Location: Westin St. Francis, San Francisco, California

    Webcast link:
http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=OREX

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
3. Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
4. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
5. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
6. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
7. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
8. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
9. Transition Therapeutics Announces Dates for Upcoming Corporate Events
10. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
11. Precision Therapeutics Secures $43 Million in Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, ... Murthy explains how he was inspired to practice medicine at an early age by ... about more than making diagnoses and prescribing medicine,” he states. “It is about building ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Kleyne Hour Power of Water, Global Climate Change and Your Health radio program ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
(Date:12/2/2016)... 1, 2016 The concept of rare diseases and ... to this sector has been taking shape in ... political aspects and initiatives related to orphan medicinal products have ... level of member states individually. Many member states in the ... space of orphan medicinal products, the result of which took ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: